Crossbow Therapeutics, Inc
Bhupal Ban, Ph.D., serves as the Associate Director of Antibody Discovery, Engineering, and Development at Crossbow Therapeutics, Inc., since August 2022. With extensive experience in the biotechnology sector, Bhupal Ban has led efforts in antibody discovery and engineering, including pMHC antigen preparation for T-cell mimic platforms and targeting intracellular cancer in bispecific formats. Previous roles include Senior Scientist positions at Entrada Therapeutics and Indiana Biosciences Research Institute, where contributions focused on antibody engineering and discovery against cytosolic targets employing high-throughput technologies. Bhupal Ban's academic background includes a Ph.D. in Biochemistry and Molecular Biology from Tulane University School of Medicine and a Master's in Organic Chemistry from Tribhuvan University.
This person is not in any offices
Crossbow Therapeutics, Inc
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.